If you need some biotech reading over Thanksgiving check out @ApexOnco previews of #ASH25 --> https://t.co/cqsR1AVbPH Starts in just over a week! $ACLX $ONC $CRVS $TERN $KURA $SNDX $CGEM $INCY
Kura Oncology $KURA secures approval for leukemia drug, its first https://t.co/auM9dGn08Y $SNDX
$KURA Komzifti approved for r/r NPM1 mutated AML. Here's the label: https://t.co/T0ZLLP4K1C Black box safety warning for differentiation syndrome but not for QTc prolongation or TdP. Label does include general warning for QTc prolongation. Will compete with $SNDX Revuforj.
Fun fact: $KURA filed the Komzifti trademark 2 years ago. https://t.co/bEmBDOOJL7
@PirateWaffle @biotech_hunter @monaco_biotech In a month, they will have a second drug without the risk. $KURA
@monaco_biotech I told you why $SNDX is down despite the approval. I'm not punishing a ticker. Whether other drugs have black box warnings is irrelevant. What matters here is competition from $KURA 's drug, with a Nov. 30 PDUFA date. The label will tell the tale, but Kura's drug appears to be better tolerated. No QTc issues.
Kudos to $KURA for this type of transparency #ESMO25 https://t.co/TjQaaqjjWG
Likely explanation for $KURA's farnesyltransferase pivot to darlifarnib / KO-2806
